ReviewLiver international : official journal of the International Association for the Study of the Liver2012
Barriers to hepatitis C treatment.
Review in Liver international : official journal of the International Association for the Study of the Liver, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03791814 (A Prospective Cohort Study to Improve HCV Care Using Multidisciplinary Approach to the Treatment of Chronic Hepatitis C in Dialysis Patients), which is not on this map. Cited by 75 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective Cohort Study to Improve HCV Care Using Multidisciplinary Approach to the Treatment of Chronic Hepatitis C in Dialysis Patients: The MATCH-D Study
Who cites it
75 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prevalence and high risk behaviours associated with HCV testing among people who inject drugs: a systematic review and Meta-analysis.Substance abuse treatment, prevention, and policy · 2020Pooled it
- Pooled it
- Health Department Efforts to Increase Hepatitis C RNA Testing Among People Appearing Out of Care: Comparison of Outreach Approaches, New York City, 2017.Public health reports (Washington, D.C. : 1974)Trial
- Comorbidities Associated With Chronic Hepatitis C Among Medicaid Beneficiaries, 2016-2020.American journal of preventive medicine · 2026Article
- Regional epidemiological study of hepatitis B, hepatitis C, and human immunodeficiency virus among prisoners.BMC public health · 2025Article
- A Bibliometric Analysis of the HCV Drug-Resistant Majority and Minority Variants.International journal of environmental research and public health · 2025Article
- Article
- Progress Toward Hepatitis C Virus Elimination among People Living with HIV-Hepatitis C Virus Coinfection in Canada.Canadian liver journal · 2025Article
- Patient-Identified Barriers to Hepatitis C Treatment.PRiMER (Leawood, Kan.) · 2025Article
- Hepatitis C Care in the Greater New Orleans Area: Patient Perspectives on the Barriers and Facilitators to Care.Journal of health care for the poor and underserved · 2025Article
- Results from a retrospective case finding and re-engagement exercise for people previously diagnosed with hepatitis C virus to increase uptake of directly acting antiviral treatment.BMC public health · 2024Article
- Barriers to accessing hepatitis B medication: a qualitative study from the USA and Canada.BMJ open · 2024Article
- Tools Needed to Support Same-Day Diagnosis and Treatment of Current Hepatitis C Virus Infection.The Journal of infectious diseases · 2024Article
- Patients' experience of accessing hepatitis C treatment through the Myanmar national hepatitis C treatment program: a qualitative evaluation.BMC health services research · 2024Article
- Implementation of a mobile health clinic framework for Hepatitis C virus screening and treatment: a descriptive study.Lancet regional health. Americas · 2024Article
- The Incidence and Care Cascade of the Hepatitis C Virus in Korea.Gut and liver · 2023Article
- Evaluation of and implications for a novel hepatitis C e-consult direct-to-treatment pilot program.Scientific reports · 2023Article
- Prospects for developing an Hepatitis C virus E1E2-based nanoparticle vaccine.Reviews in medical virology · 2023Review
- Alpha-mangostin, piperine and beta-sitosterol as hepatitis C antivirus (HCV): In silico and in vitro studies.Heliyon · 2023Article
- Time-to-hepatitis C treatment initiation among people who inject drugs in Melbourne, Australia.Epidemiology and infection · 2023Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Despite the availability of highly effective therapy for hepatitis C virus (HCV) infection, few patients receive treatment. Barriers arising at multiple levels, from diagnosis to specialist referral, may impede the delivery of hepatitis C care. At the patient level, lack of awareness, fear of side effects, poor adherence and comorbid conditions may prevent treatment. For providers, limited knowledge, lack of availability and communication difficulties may be problematic. At the government and payer level, a lack of promotion, surveillance and funding may interfere. Each of these barriers needs to be addressed if wider implementation of antiviral therapy is to be achieved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.